開示日時：2022/04/28 08:00:00
損益
| 決算期 | 売上高 | 営業益 | 経常益 | EPS |
| 2018.06 | 642,689 | 291,098 | 313,640 | 17.79 |
| 2019.06 | 721,662 | 357,978 | 374,093 | 21.33 |
| 2020.12 | 1,167,725 | 699,132 | 710,740 | 34.26 |
※金額の単位は［万円］
株価
| 前日終値 | 50日平均 | 200日平均 | 実績PER | 予想PER |
| 2,383.0 | 2,698.02 | 3,924.565 | 43.33 | 51.98 |
※金額の単位は［円］
キャッシュフロー
| 決算期 | フリーCF | 営業CF |
| 2018.06 | -144,900 | 102,272 |
| 2019.06 | 428,592 | 448,094 |
| 2020.12 | 114,647 | 173,273 |
※金額の単位は［万円］
▼テキスト箇所の抽出
April 28, 2022 Contact: E-mail: Name of Company: PeptiDream Inc. Name of Representative: Patrick C. Reid, Representative Director, CEO (Securities Code: 4587 TSE Prime Market) Yuko Okimoto, Director, Head of Investor Relations y-okimoto@peptidream.com PeptiDream Announces Initiation of PhI Study by Bristol-Myers Squibb PeptiDream Inc. (“PeptiDream”) today announced that Bristol-Myers Squibb (“BMS”) has initiated a PhI Study investigating a candidate derived from PeptiDream’s Peptide Discovery Platform System (“PDPS”) technology. PeptiDream, using its PDPS technology, previously identified peptide inhibitors in collaboration with BMS, and BMS previously completed a PhI study (BMS-986189) in December 2016. The newly initiated PhI study (ISRCTN17572332), led by BMS, will investigate the safety and tolerability in healthy volunteers of a derivative of the original candidate. The trial meets the criteria for deferral of publication of the full trial details, and therefore, limited information regarding the trial will be disclosed. The financial impact of the trial on the Company’s business results for the fiscal year ending December 2022 are expected to be minor. 1
